Breaking News, Collaborations & Alliances

Cryoport Expands Cold Chain Agreement with Stemedica

Will support a Phase II clinical trial to assess a stem cell therapy for Alzheimer's

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cryoport has expanded its contract with Stemedica Cell Technologies to provide cold chain logistics support for a Phase II clinical trial to assess the safety, tolerability and preliminary efficacy of allogeneic stem cell-based therapies in the treatment of Alzheimer’s disease.  Cryoport has worked with Stemedica since 2015, transporting ischemic-tolerant stem cells to clinical research institutions and accredited hospitals worldwide for use in preclinical and clinical studies. Stemedic...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters